Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies
Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes. Although wild-type full-length NUP98 is a member of the nuclear pore complex, the chromosomal translocations leading to NUP98 gene fusions i...
Gespeichert in:
| Veröffentlicht in: | Blood Jg. 136; H. 20; S. 2275 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
12.11.2020
|
| Schlagworte: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes. Although wild-type full-length NUP98 is a member of the nuclear pore complex, the chromosomal translocations leading to NUP98 gene fusions involve the intrinsically disordered and N-terminal region of NUP98 with over 30 partner genes. Fusion partners include several genes bearing homeodomains or having known roles in transcriptional or epigenetic regulation. Based on data in both experimental models and patient samples, NUP98 fusion oncoprotein-driven leukemogenesis is mediated by changes in chromatin structure and gene expression. Multiple cofactors associate with NUP98 fusion oncoproteins to mediate transcriptional changes possibly via phase separation, in a manner likely dependent on the fusion partner. NUP98 gene fusions co-occur with a set of additional mutations, including FLT3-internal tandem duplication and other events contributing to increased proliferation. To improve the currently dire outcomes for patients with NUP98-rearranged malignancies, therapeutic strategies have been considered that target transcriptional and epigenetic machinery, cooperating alterations, and signaling or cell-cycle pathways. With the development of more faithful experimental systems and continued study, we anticipate great strides in our understanding of the molecular mechanisms and therapeutic vulnerabilities at play in NUP98-rearranged models. Taken together, these studies should lead to improved clinical outcomes for NUP98-rearranged leukemia. |
|---|---|
| AbstractList | Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes. Although wild-type full-length NUP98 is a member of the nuclear pore complex, the chromosomal translocations leading to NUP98 gene fusions involve the intrinsically disordered and N-terminal region of NUP98 with over 30 partner genes. Fusion partners include several genes bearing homeodomains or having known roles in transcriptional or epigenetic regulation. Based on data in both experimental models and patient samples, NUP98 fusion oncoprotein-driven leukemogenesis is mediated by changes in chromatin structure and gene expression. Multiple cofactors associate with NUP98 fusion oncoproteins to mediate transcriptional changes possibly via phase separation, in a manner likely dependent on the fusion partner. NUP98 gene fusions co-occur with a set of additional mutations, including FLT3-internal tandem duplication and other events contributing to increased proliferation. To improve the currently dire outcomes for patients with NUP98-rearranged malignancies, therapeutic strategies have been considered that target transcriptional and epigenetic machinery, cooperating alterations, and signaling or cell-cycle pathways. With the development of more faithful experimental systems and continued study, we anticipate great strides in our understanding of the molecular mechanisms and therapeutic vulnerabilities at play in NUP98-rearranged models. Taken together, these studies should lead to improved clinical outcomes for NUP98-rearranged leukemia. Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes. Although wild-type full-length NUP98 is a member of the nuclear pore complex, the chromosomal translocations leading to NUP98 gene fusions involve the intrinsically disordered and N-terminal region of NUP98 with over 30 partner genes. Fusion partners include several genes bearing homeodomains or having known roles in transcriptional or epigenetic regulation. Based on data in both experimental models and patient samples, NUP98 fusion oncoprotein-driven leukemogenesis is mediated by changes in chromatin structure and gene expression. Multiple cofactors associate with NUP98 fusion oncoproteins to mediate transcriptional changes possibly via phase separation, in a manner likely dependent on the fusion partner. NUP98 gene fusions co-occur with a set of additional mutations, including FLT3-internal tandem duplication and other events contributing to increased proliferation. To improve the currently dire outcomes for patients with NUP98-rearranged malignancies, therapeutic strategies have been considered that target transcriptional and epigenetic machinery, cooperating alterations, and signaling or cell-cycle pathways. With the development of more faithful experimental systems and continued study, we anticipate great strides in our understanding of the molecular mechanisms and therapeutic vulnerabilities at play in NUP98-rearranged models. Taken together, these studies should lead to improved clinical outcomes for NUP98-rearranged leukemia.Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes. Although wild-type full-length NUP98 is a member of the nuclear pore complex, the chromosomal translocations leading to NUP98 gene fusions involve the intrinsically disordered and N-terminal region of NUP98 with over 30 partner genes. Fusion partners include several genes bearing homeodomains or having known roles in transcriptional or epigenetic regulation. Based on data in both experimental models and patient samples, NUP98 fusion oncoprotein-driven leukemogenesis is mediated by changes in chromatin structure and gene expression. Multiple cofactors associate with NUP98 fusion oncoproteins to mediate transcriptional changes possibly via phase separation, in a manner likely dependent on the fusion partner. NUP98 gene fusions co-occur with a set of additional mutations, including FLT3-internal tandem duplication and other events contributing to increased proliferation. To improve the currently dire outcomes for patients with NUP98-rearranged malignancies, therapeutic strategies have been considered that target transcriptional and epigenetic machinery, cooperating alterations, and signaling or cell-cycle pathways. With the development of more faithful experimental systems and continued study, we anticipate great strides in our understanding of the molecular mechanisms and therapeutic vulnerabilities at play in NUP98-rearranged models. Taken together, these studies should lead to improved clinical outcomes for NUP98-rearranged leukemia. |
| Author | Klco, Jeffery M Michmerhuizen, Nicole L Mullighan, Charles G |
| Author_xml | – sequence: 1 givenname: Nicole L surname: Michmerhuizen fullname: Michmerhuizen, Nicole L organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 2 givenname: Jeffery M surname: Klco fullname: Klco, Jeffery M organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 3 givenname: Charles G surname: Mullighan fullname: Mullighan, Charles G organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32766874$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkDlPxDAQhS20iD2gp0IpabL4iuOUaMUlLUfB1tEkmSRGiR3spODfE8QioVe80dOn0cxbk4V1Fgm5ZHTLmOY3RedcteWUU0pTmokTsmIJ1zGdk8W_eUnWIXxQyqTgyRlZCp4qpVO5Is0zli1YE0ZTRsYG07RjiMBW0eBGtKOBLhpb9DDg9IPAMHgHZYshqp2PXg5vmY49gvdgG6yiFnsYXeeame2hM40FWxoM5-S0hi7gxdE35HB_9757jPevD0-7231cSpqMMdSJKhVUqSq4YEoAKxQozQpaV6ouUok645IlohBYSlGpTCeKsgy0lDj_xDfk-nfvfObnhGHMexNK7Dqw6KaQcymYnsXEjF4d0anoscoHb3rwX_lfOfwbVsJp7A |
| CitedBy_id | crossref_primary_10_1080_14728222_2024_2443577 crossref_primary_10_1038_s41573_022_00505_4 crossref_primary_10_1038_s41467_022_29336_y crossref_primary_10_1111_ijlh_14422 crossref_primary_10_1007_s00277_022_05047_8 crossref_primary_10_1002_gcc_70024 crossref_primary_10_1016_j_cancergen_2025_01_006 crossref_primary_10_1016_j_dnarep_2023_103565 crossref_primary_10_1007_s12185_024_03881_2 crossref_primary_10_1016_j_molcel_2024_12_026 crossref_primary_10_1080_07853890_2022_2164610 crossref_primary_10_1093_procel_pwad013 crossref_primary_10_1038_s41408_023_00810_0 crossref_primary_10_1016_j_cancergen_2023_11_001 crossref_primary_10_1097_HS9_0000000000000923 crossref_primary_10_1186_s13046_022_02248_x crossref_primary_10_1146_annurev_cancerbio_061421_122050 crossref_primary_10_1038_s41375_022_01619_9 crossref_primary_10_1186_s40164_021_00207_4 crossref_primary_10_1038_s41409_023_02030_3 crossref_primary_10_1038_s41594_021_00608_3 crossref_primary_10_1038_s41577_025_01130_z crossref_primary_10_3390_cancers13205184 crossref_primary_10_1007_s00277_025_06312_2 crossref_primary_10_1016_j_anndiagpath_2025_152540 crossref_primary_10_1038_s41594_021_00558_w crossref_primary_10_3390_cancers13040777 crossref_primary_10_1182_bloodadvances_2023012479 crossref_primary_10_1182_blood_2021012806 crossref_primary_10_3390_ijms25179387 crossref_primary_10_1007_s12519_025_00875_w crossref_primary_10_1111_ijlh_14239 crossref_primary_10_1007_s00277_024_05680_5 crossref_primary_10_1186_s12887_024_04954_1 crossref_primary_10_3324_haematol_2024_286537 crossref_primary_10_1111_ped_15859 crossref_primary_10_1182_bloodadvances_2022009534 crossref_primary_10_1016_j_cancergen_2024_03_004 crossref_primary_10_1002_cam4_7445 crossref_primary_10_15407_oncology_2025_02_085 crossref_primary_10_21682_2311_1267_2025_12_2_107_112 crossref_primary_10_3390_ijms22094575 crossref_primary_10_1002_pbc_29201 crossref_primary_10_1016_j_humpath_2022_02_004 crossref_primary_10_1016_j_molcel_2025_05_012 crossref_primary_10_3390_ijms26115156 crossref_primary_10_1080_10428194_2022_2047672 crossref_primary_10_1016_j_chembiol_2024_08_009 crossref_primary_10_1016_j_celrep_2024_114901 crossref_primary_10_1038_s41408_025_01325_6 crossref_primary_10_1158_2159_8290_CD_21_0674 crossref_primary_10_1007_s12185_023_03612_z crossref_primary_10_1038_s41375_024_02312_9 crossref_primary_10_1111_bjh_19962 crossref_primary_10_1038_s41409_023_02106_0 crossref_primary_10_1172_JCI184743 crossref_primary_10_1002_hem3_70013 crossref_primary_10_3390_cancers15112942 crossref_primary_10_1111_ejh_14055 crossref_primary_10_1002_pbc_30021 crossref_primary_10_1097_MOH_0000000000000629 crossref_primary_10_3389_fonc_2022_1036511 crossref_primary_10_1111_bjh_70096 crossref_primary_10_1007_s00432_024_05881_5 crossref_primary_10_1007_s00441_025_03974_2 crossref_primary_10_1038_s41467_025_59930_9 crossref_primary_10_1126_sciadv_ads7876 crossref_primary_10_1172_JCI191355 crossref_primary_10_1016_j_jtct_2025_07_012 crossref_primary_10_1182_bloodadvances_2021006064 crossref_primary_10_1016_j_celrep_2023_112884 crossref_primary_10_1002_1873_3468_14728 crossref_primary_10_3389_fcell_2023_1170622 crossref_primary_10_1186_s40001_024_02042_9 crossref_primary_10_1111_bjh_19678 crossref_primary_10_1186_s12887_024_05007_3 crossref_primary_10_1080_10428194_2021_1966784 crossref_primary_10_4274_tjh_galenos_2025_2024_0391 crossref_primary_10_1002_pbc_31657 crossref_primary_10_1038_s41408_024_01066_y crossref_primary_10_1182_blood_2021011694 crossref_primary_10_1097_BS9_0000000000000232 crossref_primary_10_3389_fonc_2024_1396655 crossref_primary_10_1182_bloodadvances_2024012960 crossref_primary_10_1038_s41392_023_01649_4 crossref_primary_10_1002_hem3_90 crossref_primary_10_1186_s12920_021_00979_y crossref_primary_10_1038_s41589_023_01376_5 crossref_primary_10_1016_j_mpdhp_2025_08_001 crossref_primary_10_1182_blood_2022016889 crossref_primary_10_1186_s12885_024_12679_8 crossref_primary_10_1038_s41576_024_00780_4 crossref_primary_10_1038_s41588_025_02321_z crossref_primary_10_1016_j_heliyon_2024_e34035 crossref_primary_10_1016_j_jbc_2023_104867 crossref_primary_10_1093_nar_gkaf056 |
| ContentType | Journal Article |
| Copyright | 2020 by The American Society of Hematology. |
| Copyright_xml | – notice: 2020 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood.2020007093 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 32766874 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R35 CA197695 – fundername: NCI NIH HHS grantid: U54 CA243124 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AFETI AFOSN AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 |
| ID | FETCH-LOGICAL-c405t-af56c6ad76b23163a1b6a681b0fd6fb74e8924153b3ec43d69856019a844e7662 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 105 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000590565800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Nov 09 09:15:28 EST 2025 Mon Jul 21 06:01:44 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Language | English |
| License | 2020 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c405t-af56c6ad76b23163a1b6a681b0fd6fb74e8924153b3ec43d69856019a844e7662 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 32766874 |
| PQID | 2431818113 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2431818113 pubmed_primary_32766874 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-12 20201112 |
| PublicationDateYYYYMMDD | 2020-11-12 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2020 |
| SSID | ssj0014325 |
| Score | 2.6275911 |
| SecondaryResourceType | review_article |
| Snippet | Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor patient outcomes.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2275 |
| SubjectTerms | Animals Hematologic Neoplasms - genetics Humans Nuclear Pore Complex Proteins - genetics Oncogene Proteins, Fusion - genetics |
| Title | Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32766874 https://www.proquest.com/docview/2431818113 |
| Volume | 136 |
| WOSCitedRecordID | wos000590565800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB1B-SgX2i5QPkplpKo3i03stZ1TBQjUA7vaQ0F7W9mxveJAdiFLJf59Z5xEcEGqxCXKJXLkTGbe-M3MA_ihTbQuFJiWeF9y6QcZt5l2XIcgtHbO5onBv73Wo5GZTIpxe-BWt2WVnU9MjtrPSzojP80x0mFwyTLxa_HASTWK2NVWQmMV1gRCGbJqPXlhEaRIoqsYogwnXNTRlCY_TWXhmB5Sp4ruE-38FsBMgebq03tf8TNstxCTnTU28QVWQtWDnbMK0-v7Z_aTpaLPdJreg43z7u7jRSf91oPNYcu478BsGKg3OI1zZndVTbl8zWzl2WK-pEojXOlVDxfrZpSHmiEcZqObcWH4IxUEUxeDZ2lGbONw2T3mALNGHrjehZuryz8Xv3krzsBLxHhLbuNAlcp6rRxCRCVs5pRVCIL70avotAymIHQgnAilFF4VhpK_whopg1Yq34MP1bwK-8AigkzfjzKEnJSQbaGdGUhVGu-FjtEcwEm331PcCGI0bBXmT_X0ZccP4Gvz0aaLZkrHVOS4itHy8D-ePoItMgXqMczyb7AW8dcPx7Be_l3e1Y_fk1XhdTQe_gOAINfz |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanistic+insights+and+potential+therapeutic+approaches+for+NUP98-rearranged+hematologic+malignancies&rft.jtitle=Blood&rft.au=Michmerhuizen%2C+Nicole+L&rft.au=Klco%2C+Jeffery+M&rft.au=Mullighan%2C+Charles+G&rft.date=2020-11-12&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=136&rft.issue=20&rft.spage=2275&rft_id=info:doi/10.1182%2Fblood.2020007093&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |